Application of heart-nourishing dawayimisic preparation

A preparation, technology of atherosclerosis, applied in the field of biopharmaceuticals

Inactive Publication Date: 2020-06-30
新疆维吾尔药业有限责任公司
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is disclosed in the prior art that Yangxin Dawa Yimixikemi Ointment is often used to prevent and treat coronary atherosclerotic heart disease, but there is no report on atherosclerosis other than heart disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of heart-nourishing dawayimisic preparation
  • Application of heart-nourishing dawayimisic preparation
  • Application of heart-nourishing dawayimisic preparation

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0068] The preparation method of above-mentioned 3 kinds of preparations is identical, and preparation method comprises the following steps:

[0069] (1) Take the five flavors of rose, silkworm cocoon, fragrant green orchid, pine cone, and barberry fruit, add water and decoct twice, the first time for 2.5 hours, and the second time for 2 hours, combine the decoction, filter, and concentrate the filtrate to The relative density is 1.35~1.38g / cm 3 (50°C) clear paste;

[0070] (2) Get the apples, remove the peel and seeds, add water to decoct for 1 hour, filter, and add 400 parts by weight of sucrose to the filtrate to make syrup;

[0071] (3) In addition to musk, silver foil, gold foil and the original medicinal materials in steps (1) and (2), crush the other seventeen ingredients such as pearls into fine powder, sieve, and mix;

[0072] (4) Take musk, silver foil, gold foil and mix with the fine powder obtained in step (3); add the syrup obtained in step (2) and the clear pas...

Embodiment 1

[0074] Example 1 Effect of Yangxin Dawa Yimixike Preparation on Serum Blood Lipid Levels of Experimental Animals

[0075] Blood was collected from the experimental animals at the sixth week and the end of the tenth week of the experiment, and the blood lipid LDL (low-density lipoprotein), TC (total cholesterol), and TG (triglyceride) levels were detected on the serum samples of the animals. The detection of blood lipid LDL, TC, and TG levels adopts conventional techniques in the art. The experimental results are shown in Tables 1, 2 and Figure 1~6 . As can be seen from the experimental results, compared with the high-fat feed model group (which can be referred to as the model group for short), the serum LDL, TC, and TG levels of the low-dose group significantly decreased after six weeks of administration, while the serum LDL, TC, and TG levels of the middle-dose and high-dose groups were significantly reduced. The levels of TC and TG decreased to some extent, but there was ...

Embodiment 2

[0082] Example 2 Effect of Yangxin Dawa Yimixike Preparation on Serum Liver and Kidney Function of Experimental Animals

[0083] Routine detection of alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea (Urea), and creatinine (Cre) was performed on the collected animal serum samples. The experimental results are shown in Tables 3, 4 and Figure 7-12 . It can be seen from the experimental results that compared with the model group, the levels of ALT, AST, Urea, and Cre in the administration group did not increase significantly, suggesting that the Yangxin Dawa imixic preparation has no obvious liver and kidney toxicity.

[0084] Table 3 Sixth week experimental animal serum liver function index level (mmol / L)

[0085]

[0086]

[0087] Note: Compared with the model group, *P<0.05; **P<0.01, ***P<0.001; compared with the normal group #P<0.05; ##P<0.01, ###P<0.001.

[0088] Table 4 The level of serum liver function index (mmol / L) of experimental animals i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a heart-nourishing dawayimisic preparation and particularly application of the heart-nourishing dawayimisic preparation in preparing a medicine for preventing and treating atherosclerosis or a medicine for reducing blood fat. the heart-nourishing dawayimisic preparation comprises moschus, lignum santali albi, pearls, mastich, cortex cinnamomi, rumex dentatusflowers, silk cocoons, wood of Chinese eaglewood, stigma croci, herb or roots of operculina turpethum, tabasheer, apples, barks of pterocarpus santalinus, seeds of coriandrum sativum, roses, fructus amomi rotundus, amur barberry fruits, limonium gmelinii, portulaca oleracea seeds, thin gold pieces, thin silver pieces, amber, long usnea filaments, centaurea ruthenica roots, fructus phyllanthi and herb of dracocephalum moldavica. The heart-nourishing dawayimisic preparation has beneficial influence in relieving hyperlipidemia and reducing atherosclerotic plaques, inflammatory factor levels in serum of experiment animals show that the heart-nourishing dawayimisic preparation has a certain anti-inflammation effect, and hepatic and renal function indexes of the serum of the experiment animals show that the heart-nourishing dawayimisic honey ointment has no conspicuous hepatic or renal toxicity with an experiment dosage.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, and in particular relates to the application of a Yimixike preparation of Yangxin Dawa, especially in the preparation of drugs for preventing and treating atherosclerosis or reducing blood lipid. Background technique [0002] Atherosclerosis (AS) is the main cause of coronary heart disease, cerebral infarction and peripheral vascular disease. Lipid metabolism disorder is the basis of atherosclerosis, which is characterized by the involvement of arterial lesions starting from the intima, usually with accumulation of lipids and complex carbohydrates, hemorrhage and thrombosis, followed by fibrous tissue hyperplasia and calcium deposition, followed by There is gradual degeneration and calcification of the arterial media, resulting in thickening and hardening of the arterial wall and narrowing of the vascular lumen. Atherosclerosis is named for the yellow atheroid appearance of the lipid buildup in...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/9064A61P9/10A61P3/06A61P29/00A61K35/55A61K35/618A61K35/64A61K33/38A61K35/10A61K33/242
CPCA61K33/24A61K33/38A61K35/10A61K35/55A61K35/618A61K35/64A61K36/09A61K36/185A61K36/23A61K36/28A61K36/29A61K36/39A61K36/47A61K36/48A61K36/53A61K36/54A61K36/70A61K36/73A61K36/738A61K36/835A61K36/88A61K36/899A61K36/9064A61K2236/331A61K2236/39A61K2236/51A61P3/06A61P9/10A61P29/00A61K2300/00
Inventor 尹强尹海龙穆丹丹周琴宋菲田芳左明明刘子甲玛依热·热夏提姜大军张鹏
Owner 新疆维吾尔药业有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap